|
|
|
| Why Phase I Success Starts Long Before The Clinic | Article | By Dr. Brett Wagner and Dr. Peter Surman, Douglas CDMO | By integrating scientific rigor, regulatory foresight, and market awareness into early-stage planning, companies can leverage a robust TPP to optimize decision-making and development. |
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | “Given our industry, with so much forward risk, my overall philosophy is not to necessarily get stuck on pricing," says a commercially successful outsourcing veteran, although he quickly adds, “I don’t broadcast this externally, or even internally – quote me anonymously!" I did, and he proceeded to provide intriguing insight into working with CDMOs. | |
|
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
| A Roadmap To Expedited Review Pathways | Article | Quotient Sciences | Accelerated development and manufacturing timelines provide developers with paths to move new therapies to market quickly while still maintaining a balance of risk/benefit assessment. |
|
|
| How A Specialized CDMO De-Risks Complex API Development | Article | By Tobias Haag and Jason Modest, MilliporeSigma | Rising API complexity and AI-driven chemistry require specialized CDMOs with technical expertise in hazardous or chiral synthesis to successfully navigate the transition to GMP manufacturing. |
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
